Nereid Therapeutics applies technologies in biomolecular condensates to discover new disease treatments. Its drug discovery platform uses proprietary technologies developed in the Brangwynne Lab to generate, visualize, and measure liquid-liquid phase separation in living mammalian cells using advanced microscopy and computer vision. The company's near-term efforts will focus on certain cancers and neurodegenerative disorders in which pathological protein behaviors are governed or influenced by phase transitions. Nereid is headquartered in Boston, MA and raised $50M in Series A funding. Apple Tree Partners created Nereid with Clifford P. Brangwynne and made the founding investment; Brangwynne will chair the Scientific Advisory Board and hold a board observer seat. The company is led by interim CEO Spiros Liras and its Board is chaired by Seth Harrison, with Michael Ehlers and Robert J. Hugin among board members.

Total raised

$50M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2020